iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024
iCAD announced new research showcasing the ProFound AI Risk algorithm’s efficacy in breast cancer risk prediction. Presented at the Society for Imaging Informatics in Medicine (SIIM) Annual Meeting, the study highlights the AI's ability to identify high-risk individuals by analyzing changes in mammographic features. The research suggests a two-fold increase in risk for every 0.2 unit increase in the AI-derived score.
Additionally, iCAD introduced ProFound Cloud, a SaaS platform built on Google Cloud. This platform provides scalable, secure, and cost-effective access to the company's breast health AI solutions, enhancing diagnostic accuracy and operational efficiency. Preliminary data shows it processes cases 50% faster than traditional methods. Healthcare providers can integrate these solutions to improve patient outcomes while reducing infrastructure costs.
- ProFound AI Risk demonstrated strong predictive power for breast cancer, with a two-fold increase in risk for every 0.2 unit score increase.
- ProFound Cloud offers over 50% faster processing times compared to traditional methods, enhancing operational efficiency.
- The study is retrospective and preliminary, possibly requiring further validation before widespread clinical adoption.
Insights
The introduction of iCAD’s ProFound AI Risk algorithm is a significant development in breast cancer detection. Traditional models have often relied on static factors such as age and family history, but the use of AI to analyze changes in mammographic features between scans represents a more dynamic and potentially more accurate method of assessing breast cancer risk. This advancement could lead to earlier interventions and better patient outcomes, particularly for those who may have been classified as low risk in traditional assessments but show significant changes in AI-derived risk scores over time.
Another important point is the practical application of AI in a clinical setting. By focusing on precise risk prediction through continuous monitoring, healthcare providers can tailor screening and intervention strategies to individual needs. This personalized approach can be particularly beneficial for high-risk patients and may help in reducing the incidence of advanced-stage breast cancer through earlier detection.
The launch of ProFound Cloud is a strategic move that leverages the scalability and flexibility of the Google Cloud Platform (GCP). By offering a SaaS model, iCAD can provide continuous updates and improvements to its AI suite without the need for extensive on-premises infrastructure. This model significantly lowers the barrier to entry for smaller healthcare providers, enabling them to access cutting-edge AI technology that was previously only available to larger institutions.
The reported 50% improvement in processing time is noteworthy. Faster processing times can lead to quicker diagnoses, reducing patient anxiety and wait times. Moreover, the secure and scalable nature of ProFound Cloud ensures that it can handle large volumes of data while maintaining patient confidentiality—a critical factor in healthcare.
Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD’s Breast Health Suite of AI Solutions
NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service (SaaS) platform that offers medical providers a cost-effective, secure, and scalable solution for accessing and deploying the latest ProFound Breast Health Suite of AI solutions.
Mark Traill, M.D., a breast radiologist from the University of Michigan Health-West, will present his promising research, “The Change in Image-Derived AI-Based Risk Scores to Identify Women at an Increased Likelihood of Breast Cancer,” during SIIM Session 2022 on June 27 at 4:15 pm ET.
“Dr. Traill’s latest research is a significant step forward in the application of iCAD’s ProFound AI Risk for breast cancer risk assessment. The ability to identify women with a higher likelihood of breast cancer by analyzing changes in AI-derived risk score between a woman’s prior and current mammogram will facilitate earlier intervention and improve outcomes,” said Dana Brown, president and CEO of iCAD.
“Additionally, with our ProFound Cloud platform, we are enabling healthcare providers to seamlessly integrate our suite of solutions, including ProFound AI for Digital Breast Tomosynthesis (DBT), ProFound AI Risk, and ProFound AI for 2D Mammography into their practice, ensuring that more women can benefit from early and accurate breast cancer detection through a cost-effective, secure and scalable SaaS solution.”
Clinical Abstract Highlights
Dr. Traill’s study investigates how changes in AI-derived risk scores from prior to current mammograms can serve as a metric for calculating breast cancer risk. The retrospective study analyzed risk score changes between prior and current DBT mammograms in cohorts of 514 controls and 52 cancers. ProFound AI Risk predicts one-year absolute breast cancer risk by extracting mammographic features, density and age.
The results indicate that a change in AI-derived risk score between a woman’s prior and current mammograms is a strong predictor of breast cancer risk, with a two-fold increase in risk for every 0.2 unit increase in the score. Notably, a significant proportion of women initially classified as low risk showed a substantial increase in risk at their subsequent mammogram.
“This study is important because it helps us identify women at a very high, short-term risk of breast cancer by analyzing changes in AI-derived risk scores between mammograms,” said Dr. Traill. “By using advanced AI technology such as ProFound AI Risk, we can offer more personalized screening, ongoing surveillance or interventions as needed.
“Our preliminary results showed that risk score change over time was a very strong metric for developing breast cancer,” continued Dr. Traill. “Moreover, our preliminary results significantly outperformed other existing risk models for the ultra-short-term development of breast cancer. AI measurements over time are very good at determining something has changed in the breast tissue since the prior mammogram.”
ProFound Cloud Highlights
Built on Google Cloud Platform (GCP), ProFound Cloud enables healthcare providers to integrate cutting-edge AI technology into their practice seamlessly, enhancing diagnostic accuracy, operational efficiency, and patient outcomes.
ProFound Cloud provides advanced capabilities such as continuous updates, scalability, and secure data handling. It allows for the rapid deployment of AI solutions, minimizing the need for extensive on-premises infrastructure and reducing the total cost of ownership for healthcare providers. This flexibility ensures that facilities of all sizes can benefit from the latest advancements in breast health AI technology.
“Our ProFound Cloud platform is designed to democratize access to advanced AI solutions, making it feasible for healthcare providers of all sizes to benefit from our leading breast health technologies. Early performance results from the first 15,000 ProFound AI cloud cases show an impressive processing time that is over
“ProFound Cloud signifies a remarkable leap forward in mammography, offering our imaging network across the Las Vegas Valley a unified and cutting-edge Breast AI technology solution,” stated Angie Cosca, Chief Information Officer at Steinberg Diagnostic Medical Imaging (SDMI), an early Cloud customer. “This new innovation will enhance our operational efficiency and elevate the quality of care we provide to our patients.”
Attendees of SIIM 2024 are invited to visit iCAD’s booth #413 to learn more about ProFound Cloud and its Breast Health Suite of AI solutions. Dr. Mark Trail will also discuss his findings in iCAD’s booth on Thursday, June 27, from 2:30 to 4:15 p.m. and on Friday, June 28, from 10:30 a.m. to 12:30 p.m. ET.
To connect with the iCAD team at SIIM or schedule a virtual demo, visit our event page.
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
CONTACTS
Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com
FAQ
What did iCAD announce at the SIIM 2024 Annual Meeting?
What is the effectiveness of iCAD's ProFound AI Risk algorithm?
What is ProFound Cloud by iCAD?
How does ProFound Cloud improve operational efficiency?
When and where will Dr. Mark Traill present his research on ProFound AI Risk?
